The new COVID-19 boosters that target the omicron subvariants are more effective at preventing infections than the original vaccines, according to the first real-world data released by the U.S. Centers for Disease Control and Prevention. But some scientists say the benefits are modest at best.
Pfizer previously announced that they now have enough data on the safety and efficacy of an RSV vaccine to protect infants. Experts say this vaccine would surely help almost all families as thousands of parents won't have to experience agony and distress if their baby is hospitalized due to RSV.
A team of researchers led by Yale School of Medicine’s Steven Kleinstein, PhD, is striving to understand why some people’s immune systems generate a robust